Show simple item record

dc.contributor.authorBanerji, U
dc.contributor.authorCook, Natalie
dc.contributor.authorEvans, J
dc.contributor.authorCandilejo, M
dc.contributor.authorRoxburgh, P
dc.contributor.authorKelly, Claire
dc.contributor.authorSabaratnam, N
dc.contributor.authorPassi, R
dc.contributor.authorLeslie, S
dc.contributor.authorKatugampola, S
dc.contributor.authorGodfrey, L
dc.contributor.authorTremayne, N
dc.contributor.authorHalbert, G
dc.contributor.authorBennett, G
dc.contributor.authorKoehler, M
dc.contributor.authorLangford, G
dc.contributor.authorPittman, M
dc.contributor.authorSymeonides, S
dc.date.accessioned2019-03-29T14:22:33Z
dc.date.available2019-03-29T14:22:33Z
dc.date.issued2018en
dc.identifier.citationBanerji U, Cook N, Evans T, Candilejo I, Roxburgh P, Kelly C, et al. A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours. Br J Cancer. 2018;119(11):42.en
dc.identifier.urihttp://hdl.handle.net/10541/621684
dc.language.isoenen
dc.titleA Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumoursen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCancer Research UK Cambridge Institute, Cambridgeen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record